Labetuzumab govitecan

DB12331InvestigationalProtein Based Therapies

Labetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.

Mechanism: Pharmacologically active on DNA topoisomerase 1 and Cell adhesion molecule CEACAM5
Curator reviewed
Code names: IMMU-130

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Labetuzumab govitecan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.